Skip to main content

Clinical trial CABL001J12301

A Phase III, multi-center, open-label, randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase

Cancers
Organ LMC
Trial status Trial open for recruitment
Investigator
Trial type
Interventional with experimental drug
Phase Trial phase 3
Academic trial Non
Sponsor Novartis
EudraCT Identifier 2021-000678-27
Inclusion criteria 1.Male or female patients ? 18 years of age.2.Patients with CML-CP within 3 months of diagnosis*3.Diagnosis of CML-CP with cytogenetic confirmation of Philadelphia chromosome of (9;22) translocations (presence of BCR-ABL1 in a review of a minimum 20 m
Last update